Differently, both sequential immunotherapy (anti-PD-L1 → anti-IL-6R) and shMCT-1 treatment efficiently prevented postsurgical tumor metastasis to the lungs (Figure 5P), particularly in combination of the sequential immunotherapy with shMCT-1 effect. This evidence concerns the gene IL6R and neoplasm.